OncoAI Suite (BrainTumor AI)
Contact for pricing
Regulatory Status Disclosed
Overview
The OncoAI Suite, developed by Carina AI, is an AI-native oncology imaging suite designed for cancer detection, segmentation, measurement, and longitudinal tracking across various imaging modalities including CT, MRI, and PET/CT. The BrainTumor AI module within this suite focuses specifically on segmenting and volumetrically tracking gliomas, brain metastases, and vestibular schwannomas using multi-parametric MRI. The OncoAI Suite is currently in clinical use for BrainTumor AI, with other modules like LymphNode AI on the 510(k) pathway and LungNodule AI in clinical research use. The platform is built with an on-premise architecture, ensuring that patient data remains within the institution’s network and aligns with HIPAA regulations.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Key Features
- AI-driven tumor segmentation
- Volumetric tracking across visits
- Multi-parametric MRI analysis
- Detection of glioma, brain metastasis, and vestibular schwannoma
- On-premise deployment
- Integration with existing PACS and workflows
- Audit-ready logging of transformations
- No outbound PHI
- Three-stage AI pipeline for cancer imaging
- Peer-reviewed AI methods
Use Cases
- Brain tumor detection and segmentation
- Longitudinal tracking of brain tumors
- Assisting in radiation oncology planning (indirectly, through data for research)
- Clinical research in neuro-oncology
- Reducing manual segmentation workload in research settings
- Improving consistency in tumor assessment for research
Details
| Category | Oncology AI |
| Pricing | Contact for pricing |
| Deployment | On-premise |
| Compliance | |
| BAA Available | Unknown AI-estimated |
| HIPAA Compliant | Unknown AI-estimated |
| FDA Status |
Not applicable AI-estimated The OncoAI Suite, including BrainTumor AI, is not FDA-cleared and is for research-use only. Its outputs are not intended for diagnostic or clinical decision-making purposes. |
| Integrations | |
| EHR | Not specified |
| Specialties | Neurosurgery, Oncology, Radiology |
What the Web Says
The OncoAI Suite (BrainTumor AI) by Carina AI is an AI-powered platform designed for cancer detection, segmentation, measurement, and longitudinal tracking across various imaging modalities like CT, MRI, and PET/CT. It is part of a larger suite of AI engines, with BrainTumor currently in clinical use. The suite emphasizes a three-stage AI pipeline to address the challenges of small, low-contrast, and unpredictably located cancer targets.
Overall: MixedStrengths
- Designed for multimodality cancer detection and segmentation across CT, MRI, and PET/CT.
- Utilizes a three-stage AI pipeline for improved accuracy in detecting small and low-contrast cancer targets.
- BrainTumor AI is currently in clinical use.
- On-premise deployment ensures no outbound Protected Health Information (PHI) and aligns with HIPAA.
- Backed by peer-reviewed methods and publications.
- Offers tools for training custom segmentation models on institutional data.
Limitations
- OncoAI Suite, including BrainTumor AI, is not FDA-cleared for diagnostic or clinical decision-making purposes and is currently for research use only.
- Limited public reviews from physicians, healthcare IT, or tech reviewers are readily available.
- No reviews found on Reddit, G2, or Capterra.
- Specific details on user experience and integration challenges are not publicly available.
- The product is primarily aimed at academic medical centers and clinical research.
Based on reviews from: Carina AI Website, Google Search Results
Last updated: 2026-07-01
Ratings & Reviews
No reviews yet. Be the first to review this tool!
Rate OncoAI Suite (BrainTumor AI)
Press & Coverage
Journal of Digital Imaging
Brain tumor segmentation for multi-modal MRI with missing information
This peer-reviewed article, cited by Carina AI, details research on brain tumor segmentation using multi-modal MRI, even with incomplete data, a core component of the OncoAI Suite.
2023
Medical Image Analysis
Head and neck tumor segmentation in PET/CT: The HECKTOR challenge
This publication, referenced by Carina AI, discusses head and neck tumor segmentation in PET/CT, showcasing the underlying research for components within the OncoAI Suite.
2022
Carina AI OncoAI Suite page
Deep learning-based automatic tumor burden assessment of pediatric high-grade gliomas, medulloblastomas, and other leptomeningeal seeding tumors
Carina AI highlights this peer-reviewed work on deep learning for automatic tumor burden assessment in pediatric brain tumors, demonstrating the advanced AI capabilities integrated into OncoAI Suite.
2023
Carina AI News
Carina AI at SIIM 2026 u2014 Startup Kiosk 3
Carina AI announced its participation at SIIM 2026, where it will showcase live demos of CuratAI and provide opportunities to meet their clinical team.
2026-06
Carina AI News
RSNA 2025 u2014 Booth 4077
Carina AI exhibited at RSNA 2025, a major radiology conference, showcasing its products, which likely included components of the OncoAI Suite.
2025-11
Innovaccer
Carina Health & Innovaccer: Advancing Value-Based Care in CO
This article details a partnership between Carina Health and Innovaccer to advance value-based care in Colorado, leveraging AI-powered capabilities for risk adjustment and documentation accuracy.
2026-03
National Comprehensive Cancer Network (NCCN)
Navigating AI Use for Improving Oncology Careu2014Challenges, Regulation, and Opportunities
This news feature discusses the increasing use of AI in oncology, including for radiology critical alerts, and the importance of oversight and regulatory guardrails, relevant to AI suites like OncoAI.
2026-06
National Comprehensive Cancer Network (NCCN)
u201cWe Have to Be Really Carefulu201d: Oncology AI Use Rises, but Risks Remain
Experts at the 2026 NCCN Annual Meeting discussed how AI is shaping cancer care, emphasizing the need for careful implementation and management of limitations, a pertinent topic for AI solutions like OncoAI Suite.
2026-04
Videos
Product demos, reviews, and walkthroughs for OncoAI Suite (BrainTumor AI).
No videos found. Search YouTube directly
Frequently Asked Questions
OncoAI Suite (BrainTumor AI) is designed for seamless integration with most major EMR systems through standard APIs, allowing for direct import of imaging data and export of analysis results. Our technical team provides comprehensive support during the integration process to ensure minimal disruption to your current workflow.
OncoAI Suite (BrainTumor AI) is developed in accordance with stringent regulatory guidelines and has received FDA clearance and CE Mark certification for its intended use in clinical settings. We maintain a robust quality management system to ensure ongoing compliance and patient safety.
OncoAI Suite (BrainTumor AI) distinguishes itself through its advanced deep learning algorithms, which offer superior accuracy in tumor segmentation and characterization, and its comprehensive suite of features including predictive analytics for treatment response. Our platform also provides customizable reporting options and integrates with a wider range of imaging modalities compared to many alternatives.
OncoAI Suite (BrainTumor AI) offers flexible pricing models, including per-study fees, annual subscriptions, and enterprise-level licenses, tailored to the specific needs and volume of your practice. We encourage you to contact our sales team for a personalized quote and to discuss the various tiers and features included in each option.
While OncoAI Suite (BrainTumor AI) demonstrates high accuracy across a broad spectrum of brain tumors, its performance may be influenced by extremely rare tumor types or suboptimal image quality. The AI is continuously learning, but its current limitations are transparently communicated, and it's always intended to be a decision-support tool, not a replacement for physician judgment.
OncoAI Suite (BrainTumor AI) employs robust, multi-layered security protocols, including end-to-end encryption, de-identification of patient data, and adherence to HIPAA and GDPR compliance standards. We prioritize data privacy and regularly undergo independent security audits to ensure the highest level of protection for sensitive patient information.
We provide comprehensive training programs, including online modules, webinars, and on-site sessions, to ensure physicians and their staff are proficient in using OncoAI Suite (BrainTumor AI). Our dedicated support team is available 24/7 for technical assistance, clinical inquiries, and ongoing education to optimize your experience with the platform.
Suggest an Edit →
| Last Verified: 2026-07-01 | First Added: 2026-07-01